Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153591 · ClinicalTrials.gov registry record
Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 75
- Enrollment target
NCT04153591 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 75 participants.
The verdict
NCT04153591 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal evidence to support the use of DOACs for Left Atrial Appendage (LAA) thrombus and Left Ventricular Thrombus (LVT), and a lack of evidence for the use of DOACs in aortic thrombus, further research is warranted to determine the role of DOACs in the treatment of various mural thrombi in comparison to warfarin.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2019-11-05 |
| Est. Completion | 2020-06-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04153591
The ClinicalTrials.gov registry entry for NCT04153591 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04153591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04153591 about?
NCT04153591 is a clinical study titled "Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus". To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal e...
What is the current status of trial NCT04153591?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2019-11-05. Estimated completion is 2020-06-22.
Who is sponsoring clinical trial NCT04153591?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.